Strategy+ is advising one of the world’s premier biopharmaceutical companies Pfizer (NYSE: PFE) on the merger with global pharmaceutical company Allergan plc (NYSE:AGN). The definitive merger agreement was announced November 23, 2015. Pfizer will combine with Allergan in a stock transaction for a total enterprise value of approximately $160 billion.
Note to Editors: This press release may contain forward-looking statements regarding Strategy+’s intentions and interests. These statements are based on current expectations and assumptions that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements. The firm does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
